Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Xarelto Liability Suit: Is Label 'Silent' About Increased Bleeding Risk?

Apr 08 2018

• By Brenda Sandburg

court house

Related Content

Boehringer Avoids Pradaxa Trial, Board Chair Deposition With $650 Mil. Settlement

May 29 2014

Charting The Course Of Product Liability: From Yasmin/Yaz To Actos

Feb 20 2012

<em>Xarelto</em> Approval For AF Stroke Risk Reduction Tested FDA’s Comparative Efficacy Powers, But Conservative View Prevailed

Jun 04 2012

AbbVie AndroGel Jury Verdict Targets 'Low T' Promotion

Jul 25 2017

Product Liability Litigation Playbook: Pros And Cons For Pharma

Sep 25 2017

FDA Lifts Cloud Over J&J’s Xarelto With ROCKET-AF Re-Analysis

Oct 11 2016

Related Companies

Bayer AG

Johnson & Johnson

Boehringer Ingelheim GmbH

AbbVie Inc.

Additional Topics

United States Drug Safety Legal Issues Policy Cardiovascular BioPharmaceutical

More from Drug Safety

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window